Skip to main content
Premium Trial:

Request an Annual Quote

OICR Invests $12.6M in Cancer Research, New Equipment

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research said today that it has granted CA$12.6 million ($12.6 million) to fund new research projects and to buy equipment for research centers in Ontario, including some awards specifically for genomics and biomarker programs.

OICR awarded a total of CA$6 million to 11 research projects covering cancer biology, diagnostics, and treatment. Another CA$6.6 million was awarded to Ontario institutions to buy equipment that will be used in all stages of cancer research, from lab discoveries to clinical trials.

Among the grantees, OICR’s Genomics Platform in Toronto, which uses genome sequencing tools to understand cancer biology, will receive CA$767,000.

In addition, Ottawa Hospital Research Institute will receive CA$353,000 to develop biomarkers that will predict the clinical benefits of cetuximab, a therapy for advanced colorectal cancer.

A researcher at Ottawa Health Research Institute was awarded CA$648,000 to use a genomic approach to validate targets for osteosarcoma.

Another researcher at Sudbury Regional Hospital has received an award of $382,000 to study tumor RNA integrity as a potential biomarker of chemotherapy response in breast cancer patients.

Filed under

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.